The Central Drugs Standard Control Organisation (CDSCO) has implemented the most significant reform to India’s Bioavailability/Bioequivalence (BA/BE) study framework in years, with the New Drugs and Clinical Trials (Amendment) Rules, 2026 taking effect on March 7, 2026. This game-changing regulation replaces lengthy approval processes with a streamlined prior intimation system for low-risk studies.
Revolutionary Prior Intimation System Now Live
Under Gazette Notification G.S.R. 46(E) dated January 20, 2026, pharmaceutical companies can now begin manufacturing for certain BA/BE studies immediately upon submitting prior intimation, without waiting for formal regulatory approval. The CDSCO Circular dated March 6, 2026, confirms that applicants need only submit online Form CT-10 as prior intimation through the National Single Window System (NSWS) portal.
This reform directly addresses industry pain points, as CDSCO processes approximately 4,000 to 4,500 BA/BE study applications annually. The new mechanism is expected to save a minimum of 90 days in drug development lifecycles, providing substantial relief to pharmaceutical researchers and manufacturers.
Digital-First Implementation Through NSWS Portal
Online Submission Process
The Directorate General of Health Services circular from March 6, 2026, announces dedicated online modules available on both the NSWS and SUGAM portals. Companies can now submit intimations for Forms CT-10, CT-12, and CT-13 through these transparent, digital channels.
Immediate Manufacturing Authorization
Upon acknowledgment of the prior intimation submission, manufacturing can commence immediately for eligible drug categories. This eliminates the traditional waiting period that previously delayed study initiation by months.
Critical Exclusions: High-Risk Categories Still Require Approval
The prior intimation system does not apply to sensitive drug categories that continue requiring full regulatory approval:
- Sex hormones
- Cytotoxic drugs
- Beta-lactam drugs
- Biologics containing live microorganisms
- Narcotic and psychotropic substances
Companies working with these categories must continue following traditional approval processes, though even these benefit from reduced timelines.
Accelerated Processing Times Across All Categories
For drug categories still requiring test licenses or regulatory approval, the 2026 Amendments cut processing timelines from 90 days to 45 days. This 50% reduction applies to manufacturing drugs for clinical trials and BA/BE studies, significantly accelerating the entire development process.
Given that CDSCO handles 30,000 to 35,000 test license applications annually, this timeline reduction will benefit thousands of pharmaceutical stakeholders across India’s regulatory ecosystem.
Compliance Requirements and Immediate Action Items
Mandatory Compliance Deadline
Companies must comply with these amendments within 45 days from the Official Gazette publication date. This makes the compliance deadline approximately mid-April 2026, requiring immediate attention from regulatory affairs teams.
Required Documentation
For prior intimation submissions, companies must:
- Complete Form CT-10 through the NSWS portal
- Ensure digital submission meets all specified requirements
- Maintain documentation for potential regulatory review
- Verify drug category eligibility for prior intimation system
Broader Regulatory Landscape Changes
Jan Vishwas Bill 2026 Decriminalization
The Jan Vishwas (Amendment of Provisions) Bill, 2026 has passed both Houses of Parliament, decriminalizing 717 provisions across 79 Central Acts. This broader reform context supports the pharmaceutical sector’s ease of doing business while maintaining safety standards.
New Compounding Framework
CDSCO has issued a Guidance Document on Compounding of Offences under the Drugs and Cosmetics (Compounding of Offences) Rules, 2025. This framework provides clarity on procedures, authorities, and immunity provisions, offering companies clearer pathways for addressing regulatory infractions.
Strategic Business Impact
These reforms represent a fundamental shift toward risk-based regulation in India’s pharmaceutical sector. Companies can now:
- Reduce drug development timelines by minimum 90 days
- Lower regulatory compliance costs through digital submissions
- Accelerate market entry for generic and biosimilar products
- Benefit from clearer, more transparent regulatory processes
Current Regulatory Framework
The updated system still operates within established guidelines including the Drugs and Cosmetics Act 1940, Schedule Y requirements, ICMR Guidelines, CDSCO BA/BE Guidelines (2018), and New Drug and Clinical Trial Rules (2019). The reforms enhance efficiency while preserving safety standards and ethical requirements.
Next Steps for Pharmaceutical Companies
Immediate actions for regulatory affairs teams include:
- Audit current BA/BE study pipeline to identify prior intimation eligible studies
- Train teams on NSWS and SUGAM portal submission processes
- Update internal SOPs to reflect 45-day processing timelines
- Review drug portfolios against excluded categories list
- Establish digital documentation systems for streamlined submissions
Companies should also prepare for increased study volumes as reduced timelines make BA/BE studies more attractive for generic drug development and market entry strategies.
ACPL’s regulatory experts can help you navigate India’s transformed BA/BE study requirements and optimize your regulatory strategy under the new framework. Contact us at info@acplgroupindia.co.in or call +91-9266665201 for a consultation.